Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.36 |
| ▸ | TYR | P14679 | 2/20 | 0.35 |
| ▸ | RARA | P10276 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | AKT1 | P31749 | 2/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | PHLPP1 | O60346 | 1/20 | 0.33 |
| ▸ | ILK | Q13418 | 1/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL971420 | 0.72 | CYP3A4 (0.38) | ALDH1A1CYP3A4HPGDTDP1PDE4D | |
| SCHEMBL5266203 | 0.70 | ALOX5 (0.41) | ALDH1A1CYP3A4HPGDTDP1PDE4D | |
| SCHEMBL12919828 | 0.70 | CYP3A4 (0.37) | ALDH1A1CYP3A4HPGDTDP1PDE4D | |
| SCHEMBL15052242 | 0.70 | ALDH1A1 (0.42) | ALDH1A1CYP3A4HPGDTDP1PDE4D | |
| SCHEMBL11014320 | 0.70 | ODC1 (0.48) | ALDH1A1PDE4DPTPN1 | |
| SCHEMBL9464495 | 0.69 | PDE4D (0.60) | ALDH1A1CYP3A4HPGDPDE4DPTPN1 | |
| SCHEMBL8722880 | 0.69 | TYR (0.41) | ALDH1A1CYP3A4HPGDTDP1PDE4D | |
| SCHEMBL9464016 | 0.66 | KDM4E (0.44) | ALDH1A1CYP3A4HPGDPDE4DPTPN1 | |
| SCHEMBL11015336 | 0.66 | ODC1 (0.44) | PDE4DIDO1 | |
| SCHEMBL8071247 | 0.66 | CA12 (0.42) | ALDH1A1CYP3A4HPGDTDP1PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160324823-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | BIOELECTRON TECHNOLOGY CORPORATION | 2016-11-10 | — | — | US | disclosed |
| US-20160324823-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | BIOELECTRON TECHNOLOGY CORPORATION | 2016-11-10 | — | — | US | disclosed |
| US-20160324823-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | BIOELECTRON TECHNOLOGY CORPORATION | 2016-11-10 | — | — | US | disclosed |
| US-20130267538-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | GALILEO PHARMACEUTICALS INC. | 2013-10-10 | — | — | US | disclosed |
| US-20130267538-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | GALILEO PHARMACEUTICALS INC. | 2013-10-10 | — | — | US | disclosed |
| US-20130267538-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | GALILEO PHARMACEUTICALS INC. | 2013-10-10 | — | — | US | disclosed |
| WO-2005032544-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | GALILEO PHARMACEUTICALS, INC. (US) | 2005-04-14 | — | — | WO | disclosed |
| US-20050065099-A1 | Alzheimer's disease; Parkinson's disease; brain disorders; antiepileptic agents; amyotrophic lateral sclerosis; vision defects | EDISON PHARMACEUTICALS, INC. | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065099-A1 | Alzheimer's disease; Parkinson's disease; brain disorders; antiepileptic agents; amyotrophic lateral sclerosis; vision defects | CLN6, LDHA, NLN | ALDH1A1 674/4885CYP3A4 2690/4885HPGD 1853/4885 |
| US-20160324823-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | NLN, FH, MFN2 | ALDH1A1 792/4885CYP3A4 3089/4885HPGD 1359/4885 |
| US-20130267538-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | NLN, FH, MFN2 | ALDH1A1 792/4885CYP3A4 3089/4885HPGD 1359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.